Concepedia

Shuqun Lin

SL

16

Publications

970

Citations

15

H-Index

1996

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Abbott Fund

Bristol-Myers Squibb (Japan)

Shuqun Lin is an author at Bristol-Myers Squibb (United States) specializing in drug discovery, pharmacology, and medicine.

Top concepts

Publications per year

1996–2019

16

Publications

16

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin et al. · Journal of Medicinal Chemistry · 2019 · 345 citations · Full text

Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)

Ryan Moslin, Yanlei Zhang, Stephen T. Wrobleski et al. · Journal of Medicinal Chemistry · 2019 · 84 citations · Full text

Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-<i>f</i>][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors

John Hynes, Alaric J. Dyckman, Shuqun Lin et al. · Journal of Medicinal Chemistry · 2007 · 81 citations · Full text

A Novel, Picomolar Inhibitor of Human Immunodeficiency Virus Type 1 Protease

Hing L. Sham, Chen Zhao, Kent D. Stewart et al. · Journal of Medicinal Chemistry · 1996 · 62 citations · Full text

Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-<i>N</i>-propylpyrrolo[1,2-<i>f</i>][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases

Chunjian Liu, James C. Lin, Stephen T. Wrobleski et al. · Journal of Medicinal Chemistry · 2010 · 57 citations · Full text

, , +18

Rows per page

1–5 of 16